Sanofi (EPA:SAN) PT Set at €81.00 by Goldman Sachs Group

Sanofi (EPA:SAN) has been assigned a €81.00 ($94.19) price target by equities researchers at Goldman Sachs Group in a note issued to investors on Monday, Borsen Zeitung reports. The brokerage currently has a “neutral” rating on the stock. Goldman Sachs Group’s target price indicates a potential upside of 12.13% from the stock’s previous close.

SAN has been the topic of several other reports. Deutsche Bank set a €92.00 ($106.98) price target on Sanofi and gave the company a “buy” rating in a research report on Monday. HSBC set a €79.00 ($91.86) price target on Sanofi and gave the company a “neutral” rating in a research report on Friday, August 2nd. JPMorgan Chase & Co. set a €81.00 ($94.19) price target on Sanofi and gave the company a “neutral” rating in a research report on Tuesday, July 30th. Jefferies Financial Group set a €90.00 ($104.65) price target on Sanofi and gave the company a “buy” rating in a research report on Friday, June 21st. Finally, Credit Suisse Group set a €82.00 ($95.35) price target on Sanofi and gave the company a “buy” rating in a research report on Tuesday, July 30th. Six equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Sanofi presently has an average rating of “Buy” and a consensus target price of €86.20 ($100.23).

Shares of EPA:SAN opened at €72.24 ($84.00) on Monday. The company has a 50-day simple moving average of €75.83. Sanofi has a 52-week low of €63.09 ($73.36) and a 52-week high of €92.97 ($108.10).

Sanofi Company Profile

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Recommended Story: How to Invest in Growth Stocks

Analyst Recommendations for Sanofi (EPA:SAN)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.